What is Intercept Pharmaceuticals?
Intercept Pharmaceuticals operates as a specialized biopharmaceutical firm dedicated to the development and commercialization of innovative treatments for chronic liver diseases. The company occupies a critical niche in hepatology, focusing on addressing significant unmet medical needs through rigorous clinical research and the identification of novel mechanisms of action. By integrating deep scientific expertise with advanced drug development capabilities, Intercept has built a sophisticated pipeline designed to address complex pathophysiology. Their operational model encompasses the entire lifecycle of therapeutic development, from initial discovery and clinical trials to manufacturing, regulatory affairs, and global market access, ensuring that investigational medicines reach patients in need of specialized care.
How much funding has Intercept Pharmaceuticals raised?
Intercept Pharmaceuticals has raised a total of $1.5B across 11 funding rounds:
Series B
$25M
Series C
$30M
Stock Offering
$75M
Stock Offering
$61.7M
Stock Offering
$183.3M
Debt
$447.7M
Stock Offering
$250M
Debt
$210.4M
Stock Offering
$200M
Series B (2010): $25M supported by Genextra S.p.A
Series C (2012): $30M featuring Genextra S.p.A and OrbiMed
Stock Issuance/Offering (2012): $75M, investors not publicly disclosed
Stock Issuance/Offering (2013): $61.7M, investors not publicly disclosed
Stock Issuance/Offering (2014): $183.3M, investors not publicly disclosed
Debt (2016): $447.7M, investors not publicly disclosed
Stock Issuance/Offering (2018): $250M featuring Genextra S.p.A and Samsara BioCapital, L.P.
Debt (2019): $210.4M, investors not publicly disclosed
Stock Issuance/Offering (2019): $200M, investors not publicly disclosed
Key Investors in Intercept Pharmaceuticals
Genextra S.p.A
Genextra is a privately owned holding company that invests in early-stage life science companies. The firm focuses on identifying innovative research in life sciences and aims to advance novel therapies and technologies through successful business initiatives.
OrbiMed
OrbiMed Advisors LLC operates as a specialized investment firm focused on the healthcare sector, with deep expertise spanning multiple therapeutic and commercial domains including biopharmaceuticals and medical devices.
Balyasny Asset Management
Balyasny Asset Management is a global investment firm focused on delivering consistent returns for institutional investors through deep research, advanced technology, and disciplined risk management across financial markets.
What's next for Intercept Pharmaceuticals?
With the support of major enterprise-level funding, Intercept Pharmaceuticals is well-positioned to accelerate its clinical development programs and expand its commercial footprint. The company's strategic focus remains on advancing its pipeline of investigational medicines while optimizing its market access capabilities. Future growth will likely be driven by the successful navigation of late-stage clinical trials and the potential expansion of therapeutic indications for its core assets. By leveraging its established expertise in liver biology and maintaining a disciplined approach to capital deployment, Intercept aims to solidify its leadership in the hepatology market and deliver long-term value to stakeholders through continued innovation in therapeutic delivery.
See full Intercept Pharmaceuticals company page
